Frontier Capital Management’s Sage Therapeutics SAGE Stock Holding History

Frontier Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-226,679	Closed	-$6.51M	–	299
2020 Q1	$6.51M	Sell	226,679 -382,062	-63%	-$22.1M	0.07%	222
2019 Q4	$43.9M	Buy	608,741 +604,867	+15,614%	+$74.4M	0.32%	119
2019 Q3	$543K	Sell	3,874 -256,851	-99%	-$43M	﹤0.01%	283
2019 Q2	$47.7M	Buy	260,725 +1,848	+0.7%	+$315K	0.36%	115
2019 Q1	$41.2M	Buy	+258,877	New	+$37.5M	0.29%	137
2017 Q2	–	Sell	-54,781	Closed	-$3.89M	–	331
2017 Q1	$3.89M	Sell	54,781 -23,860	-30%	-$1.4M	0.03%	278
2016 Q4	$4.01M	Sell	78,641 -150,313	-66%	-$7.08M	0.03%	268
2016 Q3	$10.5M	Buy	+228,954	New	+$9.32M	0.08%	237

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Frontier Capital Management's SAGE Position: Q2 2020 in Review

Frontier Capital Management sold out of Sage Therapeutics (SAGE) in Q2 2020, closing a stake of 226,679 shares — an estimated $6.51M sold.

Frontier Capital Management first reported a position in SAGE in Q3 2016 and held it in 8 quarters. The position peaked at $47.7M in Q2 2019. 217 funds tracked by Wall St. Rank hold SAGE as of Q2 2020.

Frontier Capital Management reported no remaining Sage Therapeutics position as of Q2 2020 after selling out during the quarter.
Frontier Capital Management sold 226,679 Sage Therapeutics shares in Q2 2020, an estimated $6.51M.
Frontier Capital Management first reported a position in Sage Therapeutics in Q3 2016 and held it in 8 quarters.
Frontier Capital Management's Sage Therapeutics position peaked at $47.7M in Q2 2019.
217 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2020.

Based on Frontier Capital Management's 13F filing for Q2 2020, filed 17 Jul 2020.